Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00220311
Status:
COMPLETED
Last Update Posted:
2013-12-04
First Post:
2005-09-21
Brief Title:
A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia andor Thrombocytopenia
Sponsor:
Genzyme a Sanofi Company
Organization:
Sanofi
Study Overview
Official Title:
A Multicenter Study to Confirm the Efficacy and Safety of Fludara iv Fludarabine Phosphate SH L 573 Administered in 6 Treatment Cycles 1 Treatment Cycle 5-consecutive Day Dosing Followed by an Observation Period of 23 Days in Untreated Chronic Lymphocytic Leukemia Patients With Anemia andor Thrombocytopenia
Status:
COMPLETED
Status Verified Date:
2013-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to confirm the efficacy and safety of fludarabine phosphate administered with dose increasing in 6 cycles 1 cycle 5 treatment days every 28 days in untreated chronic lymphocytic leukemia CLL patients with anemia andor thrombocytopenia
Detailed Description:
As of 29 May 2009 the clinical trial sponsor is Genzyme Corporation NOTE This study was originally posted by sponsor Schering AG Germany which was subsequently renamed to Bayer Schering Pharma AG Germany
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 90699 | None | None | None |